NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDDK E-064-2004-0-FR-39 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment FR EP 10165256.8 Expired
NIDDK E-064-2004-0-SK-55 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment SK EP 10165256.8 Expired
NIDDK E-064-2004-0-RO-52 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment RO EP 10165256.8 Expired
NIDDK E-064-2004-0-NL-50 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment NL EP 10165256.8 Expired
NIDDK E-064-2004-0-MC-48 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment MC EP 10165256.8 Expired
NIDDK E-064-2004-0-SI-54 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment SI EP 10165256.8 Expired
NIDDK E-064-2004-0-PT-51 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment PT EP 10165256.8 Expired
NIDDK E-064-2004-0-MK-49 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment MK EP 10165256.8 Expired
NIDDK E-064-2004-0-ES-37 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment ES EP 10165256.8 Expired
NIDDK E-064-2004-0-GB-40 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment GB EP 10165256.8 Expired
NIDDK E-064-2004-0-SE-53 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment SE EP 10165256.8 Expired
NIDDK E-064-2004-0-CH-31 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment CH EP 10165256.8 Expired
NIDDK E-064-2004-0-TR-56 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment TR EP 10165256.8 Expired
NHLBI E-321-2007-0-US-03 Apparatus For Countercurrent Chromatography US National Stage 12/746,436 9028693 Issued PDF
NCI E-221-2005-2-US-02 FAST ELECTRON PARAMAGNETIC RESONANCE IMAGING (EPRI) IN THE CW EPR MODE USING RAPID-SCAN IN THE PRESENCE OF ROTATING GRADIENTS AND DIRECT DETECTION WITH TRANSMIT/RECEIVE & DATA PROCESSING IN A DIGITAL SIGNAL PROCESSING PLATFORM US CON 12/794,695 8242778 Issued PDF
NIDDK E-226-2009-0-PCT-02 Use of Stamp Related Molecules in the Diagnosis and Inhibition of Ovarian Cancer Cells` PCT PCT PCT/US10/037452 Abandoned
NCI E-033-2008-0-GB-10 THERAPEUTIC APPLICATIONS OF P53 ISOFORMS IN REGENERATIVE MEDICINE, AGING AND CANCER GB EP 08850046.7 Abandoned
NCI E-033-2008-0-DE-09 THERAPEUTIC APPLICATIONS OF P53 ISOFORMS IN REGENERATIVE MEDICINE, AGING AND CANCER DE EP 08850046.7 Abandoned
NCI E-033-2008-0-FR-11 THERAPEUTIC APPLICATIONS OF P53 ISOFORMS IN REGENERATIVE MEDICINE, AGING AND CANCER FR EP 08850046.7 Abandoned
NCI E-200-2011-0-US-01 METHODS OF TREATING ABC-SUBTYPE OF DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL) USING INHIBITORS OF BRUTON'S TYROSINE KINASE US 61/351,130 Abandoned
NCI E-098-2010-0-US-01 Drug Combination Of DNA Topoisomerase (TOP1) Inhibitors And Extracellular ATP Produces A Significant Increase In Beneficial Anti-carinoma Cytotoxicity US 61/350,660 Abandoned
NCI E-176-2010-1-US-01 Soluble Glypican-3 Inhibits Cancer Growth US 61/350,722 Abandoned
NIA E-146-1993-0-JP-54 METHOD OF TREATING ATHEROSCLEROSIS USING MICROTUBULE STABILIZING AGENT JP DIV 2010-125458 Expired
NIAID E-078-2009-0-BE-07 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses BE EP 10781321.4 Abandoned
NIAID E-078-2009-0-IT-11 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses IT EP 10781321.4 Abandoned
NIAID E-078-2009-0-FR-09 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses FR EP 10781321.4 Abandoned
NIAID E-078-2009-0-DE-08 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses DE EP 10781321.4 Abandoned
NIAID E-078-2009-0-GB-10 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses GB EP 10781321.4 Abandoned
NIAID E-078-2009-0-EP-03 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses EP National Stage 10781321.4 Abandoned
NCI E-166-2007-0-US-05 Filipil Compositions And Methods For Treating Cancer US National Stage 12/745,279 8501912 Abandoned PDF
NICHD E-020-1999-0-US-05 Method of Immunizing Humans Against Salmonella Typhi Using a Vi-rEPA Conjugate Vaccine US DIV 12/790,258 8202520 Expired PDF
NIAID E-078-2009-0-PCT-02 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses (TBEV/DEN4) PCT PCT PCT/US2010/036678 Expired
NINDS E-214-2007-0-US-10 An Implanted System For Sensing, Triggering And Automatically Controlling Swallowing To Maintain Control Of Secretions US CON 12/789,659 Abandoned
NCI E-192-2010-0-US-01 The Development Of NSAID HNO Donor For Cancer And Heart Disease US 61/349,716 Abandoned
NCI E-157-2009-0-PCT-02 MDR1-Inverse Agents PCT PCT PCT/US2010/036348 Expired
NCI E-178-2009-0-PCT-02 Anti-TNF Induced Apoptosis (ATIA) Diagnostic Markers And Therapies PCT PCT PCT/US2010/36394 Expired
NIDCR E-042-2007-0-US-03 Bone Scaffolds, Injectable Bone Repair Materials And Methods For Bone Repair US National Stage 12/745,231 Abandoned
NCI E-196-2000-0-US-04 Defensin-Antigen Fusion Proteins US DIV 12/786,334 7915040 Abandoned PDF
NIAID E-050-1997-1-US-15 Method Of Sampling, Amplifying And Quantifying Segment Of Nucleic Acid US CON 12/785,989 Abandoned
NCI E-191-2009-0-EP-05 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy EP National Stage 10722881.9 Issued
NCI E-191-2009-0-GB-13 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy GB EP 10722881.9 Abandoned
NCI E-191-2009-0-CH-10 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy CH EP 10722881.9 Abandoned
NCI E-191-2009-0-FR-12 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy FR EP 10722881.9 Abandoned
NCI E-191-2009-0-DE-11 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy DE EP 10722881.9 Abandoned
NCI E-191-2009-0-AU-03 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy AU National Stage 2010249401 Abandoned
NCI E-191-2009-0-US-07 AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY US National Stage 13/322,140 8546091 Issued PDF
NCI E-191-2009-0-PCT-02 AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY PCT PCT PCT/US2010/035816 Expired
NIA E-134-2009-0-PCT-02 Engineered Biological Pacemakers PCT PCT PCT/US2010/035823 Expired
NCI E-191-2009-0-JP-06 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy JP National Stage 2012-512066 Abandoned
NCI E-191-2009-0-CA-04 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy CA National Stage 2762983 Abandoned